Last reviewed · How we verify

Epirubicin, cyclophosphamide and docetaxel

Danish Breast Cancer Cooperative Group · Phase 3 active Small molecule

Epirubicin, cyclophosphamide and docetaxel is a Combination chemotherapy regimen Small molecule drug developed by Danish Breast Cancer Cooperative Group. It is currently in Phase 3 development for Breast cancer (neoadjuvant and adjuvant treatment). Also known as: Ellence, Taxotere.

This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division, used in breast cancer treatment.

This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division, used in breast cancer treatment. Used for Breast cancer (neoadjuvant and adjuvant treatment).

At a glance

Generic nameEpirubicin, cyclophosphamide and docetaxel
Also known asEllence, Taxotere
SponsorDanish Breast Cancer Cooperative Group
Drug classCombination chemotherapy regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation. Cyclophosphamide is an alkylating agent that cross-links DNA strands. Docetaxel is a microtubule stabilizer that prevents microtubule depolymerization, blocking cell division. Together, these three drugs attack cancer cells through complementary mechanisms of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epirubicin, cyclophosphamide and docetaxel

What is Epirubicin, cyclophosphamide and docetaxel?

Epirubicin, cyclophosphamide and docetaxel is a Combination chemotherapy regimen drug developed by Danish Breast Cancer Cooperative Group, indicated for Breast cancer (neoadjuvant and adjuvant treatment).

How does Epirubicin, cyclophosphamide and docetaxel work?

This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division, used in breast cancer treatment.

What is Epirubicin, cyclophosphamide and docetaxel used for?

Epirubicin, cyclophosphamide and docetaxel is indicated for Breast cancer (neoadjuvant and adjuvant treatment).

Who makes Epirubicin, cyclophosphamide and docetaxel?

Epirubicin, cyclophosphamide and docetaxel is developed by Danish Breast Cancer Cooperative Group (see full Danish Breast Cancer Cooperative Group pipeline at /company/danish-breast-cancer-cooperative-group).

Is Epirubicin, cyclophosphamide and docetaxel also known as anything else?

Epirubicin, cyclophosphamide and docetaxel is also known as Ellence, Taxotere.

What drug class is Epirubicin, cyclophosphamide and docetaxel in?

Epirubicin, cyclophosphamide and docetaxel belongs to the Combination chemotherapy regimen class. See all Combination chemotherapy regimen drugs at /class/combination-chemotherapy-regimen.

What development phase is Epirubicin, cyclophosphamide and docetaxel in?

Epirubicin, cyclophosphamide and docetaxel is in Phase 3.

What are the side effects of Epirubicin, cyclophosphamide and docetaxel?

Common side effects of Epirubicin, cyclophosphamide and docetaxel include Neutropenia, Anemia, Thrombocytopenia, Nausea and vomiting, Alopecia, Mucositis.

Related